• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

GLP-1 激动剂治疗:对糖尿病视网膜病变筛查的影响。

GLP-1 agonist treatment: implications for diabetic retinopathy screening.

机构信息

Department of Diabetes and Endocrinology, University Hospital of North Staffordshire NHS Trust, Springfield Unit, North Buildings, Stoke-on-Trent ST4 6QG, United Kingdom.

出版信息

Diabetes Res Clin Pract. 2011 Dec;94(3):e68-71. doi: 10.1016/j.diabres.2011.08.017. Epub 2011 Sep 8.

DOI:10.1016/j.diabres.2011.08.017
PMID:21906831
Abstract

Rapid improvement in glycaemic control induced by GLP-1 agonist therapy could be yet another illustration of transient or permanent progression of diabetic retinopathy, similar to documented examples such as pregnancy and continuous subcutaneous insulin infusion. Specific guidelines would be needed to monitor this paradoxical phenomenon during treatment with GLP-1 agonists.

摘要

GLP-1 激动剂治疗引起的血糖控制迅速改善,可能是糖尿病视网膜病变的暂时或永久性进展的又一个例子,类似于妊娠和持续皮下胰岛素输注等已记录的例子。在使用 GLP-1 激动剂治疗期间,需要有具体的指南来监测这种矛盾现象。

相似文献

1
GLP-1 agonist treatment: implications for diabetic retinopathy screening.GLP-1 激动剂治疗:对糖尿病视网膜病变筛查的影响。
Diabetes Res Clin Pract. 2011 Dec;94(3):e68-71. doi: 10.1016/j.diabres.2011.08.017. Epub 2011 Sep 8.
2
[New prospects in the treatment of diabetic retinopathy. Current situation and pharmacological developments].[糖尿病视网膜病变治疗的新前景。现状与药理学进展]
MMW Fortschr Med. 2003 Apr 3;145(14):37-8.
3
[Screening and care of pregnancy in diabetics].[糖尿病患者孕期的筛查与护理]
Orv Hetil. 1993 May 2;134(18):975-7.
4
[Diabetus mellitus and pregnancy].[糖尿病与妊娠]
Oftalmologia. 2009;53(3):118-22.
5
Diabetic retinopathy. Screening and prevention of blindness. A doctoral thesis.糖尿病性视网膜病变。失明的筛查与预防。博士论文。
Acta Ophthalmol Scand Suppl. 1997(223):1-76.
6
Effect of diagnosis-time and initial treatment on the onset of type 2 diabetes mellitus complications: a population-based representative cross-sectional study in Hungary.诊断时间和初始治疗对 2 型糖尿病并发症发病的影响:匈牙利基于人群的代表性横断面研究。
Diabetes Res Clin Pract. 2011 Dec;94(3):e65-7. doi: 10.1016/j.diabres.2011.08.007. Epub 2011 Aug 30.
7
Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.皮下注射胰高血糖素样肽-1可改善早期2型糖尿病患者3周内的餐后血糖控制。
Clin Sci (Lond). 1998 Sep;95(3):325-9.
8
[Diabetes mellitus and pregnancy--the current status. II. Diabetes types 1 and 2, diabetic nephropathy and diabetic retinopathy. The effect of diabetes on pregnancy and of pregnancy on diabetes. Diagnostic monitoring].糖尿病与妊娠——现状。II. 1型和2型糖尿病、糖尿病肾病及糖尿病视网膜病变。糖尿病对妊娠的影响及妊娠对糖尿病的影响。诊断监测
Akush Ginekol (Sofiia). 1989;28(1):1-8.
9
Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.在非胰岛素依赖型糖尿病(NIDDM)患者中,通过持续给予胰高血糖素样肽-1(GLP-1)使日间血糖浓度接近正常化。
Diabetologia. 1997 Feb;40(2):205-11. doi: 10.1007/s001250050664.
10
[Continuous subcutaneous insulin infusion].
Nihon Rinsho. 1990 Dec;48 Suppl:1038-43.

引用本文的文献

1
Early worsening of diabetic retinopathy in individuals with type 2 diabetes treated with tirzepatide: a real-world cohort study.使用替尔泊肽治疗的2型糖尿病患者糖尿病视网膜病变的早期恶化:一项真实世界队列研究
Diabetologia. 2025 Jul 10. doi: 10.1007/s00125-025-06466-8.
2
New generation agents for glycemic control and diabetic retinopathy progression: what we need to know?用于血糖控制和糖尿病视网膜病变进展的新一代药物:我们需要了解什么?
Acta Diabetol. 2025 Jun 30. doi: 10.1007/s00592-025-02552-w.
3
Incretin-based therapy: a new horizon in diabetes management.
基于肠促胰岛素的疗法:糖尿病管理的新视野。
J Diabetes Metab Disord. 2024 Aug 17;23(2):1665-1686. doi: 10.1007/s40200-024-01479-3. eCollection 2024 Dec.
4
Dry Eye in Diabetes: The Indian Diabetic and Endocrine Eye Diseases (INDEED) Review.糖尿病中的干眼:印度糖尿病与内分泌眼病(INDEED)综述
touchREV Endocrinol. 2024 Oct;20(2):30-41. doi: 10.17925/EE.2024.20.2.6. Epub 2024 Oct 14.
5
Enhancing glycaemic control with impetus on weight management: Observing for early worsening of diabetic retinopathy.加强血糖控制并注重体重管理:观察糖尿病视网膜病变早期病情恶化情况。
Eye (Lond). 2024 Jul;38(10):1787-1788. doi: 10.1038/s41433-024-02980-y. Epub 2024 Feb 10.
6
Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.替尔泊肽,2型糖尿病的最新药物:文献综述及对临床实践的启示
Ann Pharmacother. 2024 Apr;58(4):444-445. doi: 10.1177/10600280231224039. Epub 2024 Jan 21.
7
Glucagon-Like Peptide-1 Receptor Agonist and Risk of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials.胰高血糖素样肽-1受体激动剂与2型糖尿病患者糖尿病视网膜病变风险:一项对随机安慰剂对照试验的系统评价和荟萃分析
Clin Drug Investig. 2023 Dec;43(12):915-926. doi: 10.1007/s40261-023-01319-x. Epub 2023 Nov 8.
8
Sodium-glucose co-transporter 2 inhibitor add-on therapy for metformin delays diabetic retinopathy progression in diabetes patients: a population-based cohort study.钠-葡萄糖共转运蛋白 2 抑制剂联合二甲双胍治疗可延缓糖尿病患者糖尿病视网膜病变的进展:一项基于人群的队列研究。
Sci Rep. 2023 Oct 10;13(1):17049. doi: 10.1038/s41598-023-43893-2.
9
Impact of Intensive Glycemic Treatment on Diabetes Complications-A Systematic Review.强化血糖治疗对糖尿病并发症的影响——一项系统综述
Pharmaceutics. 2023 Jun 22;15(7):1791. doi: 10.3390/pharmaceutics15071791.
10
Semaglutide-eye-catching results.司美格鲁肽——引人注目的结果。
World J Diabetes. 2023 Apr 15;14(4):424-434. doi: 10.4239/wjd.v14.i4.424.